MOONLAKE IMMUNOTHERAPEUTICS Operating Lease Right-of-Use Assets
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) had Operating Lease Right-of-Use Assets of $2.08 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-10
- 2026-06-30: Operating Lease, Right-of-Use Asset $2.08M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.86M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.57M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.91M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $1.86M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $1.57M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $1.91M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $2.25M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $2.59M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $2.92M 10-K · filed 2026-02-25 | $2.92M 10-K · filed 2025-02-26 |
| 2024-09-30 | $3.25M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $3.38M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $3.70M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $3.63M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $169.42K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $211.24K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $246.26K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $282.58K 10-K · filed 2024-02-29 | |
| 2022-01-01 | $435.00K 10-K · filed 2023-03-20 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |